Jounce Therapeutics to Hold Virtual Meeting of Stockholders
June 02 2020 - 8:00AM
Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company
focused on the discovery and development of novel cancer
immunotherapies and predictive biomarkers, today announced that it
will now host the Company’s 2020 Annual Meeting of Stockholders
(the “Annual Meeting”) virtually due to the public health impact of
the coronavirus (COVID-19) pandemic and to prioritize the health
and well-being of meeting participants.
As previously announced, the Annual Meeting will
be held on Friday, June 26, 2020 at 9:00 a.m. ET, but will be held
via live audio webcast. Stockholders will not be able to attend the
Annual Meeting in person. Stockholders are entitled to attend and
vote if they were a stockholder as of the close of business on
April 28, 2020, the record date, or hold a legal proxy for the
meeting provided by the stockholder’s bank, broker or nominee as of
such record date.
To access, participate in and vote at the Annual
Meeting at www.virtualshareholdermeeting.com/JNCE2020 (the “Annual
Meeting website”), stockholders must enter the control number found
on the proxy card, voting instruction form or notice they
previously received. Please note that the proxy card included with
the proxy materials previously distributed will not be updated to
reflect the change in location and may continue to be used by
stockholders to vote shares in connection with the Annual
Meeting.
All stockholders, whether or not they plan to
attend the Annual Meeting, are encouraged to vote and submit their
proxies in advance of the meeting by one of the methods described
in the proxy materials. Stockholders may also vote online during
the Annual Meeting by following the instructions available on the
Annual Meeting website.
About Jounce TherapeuticsJounce
Therapeutics, Inc. is a clinical-stage immunotherapy company
dedicated to transforming the treatment of cancer by developing
therapies that enable the immune system to attack tumors and
provide long-lasting benefits to patients through a
biomarker-driven approach. Jounce has three development-stage
programs, two of which are clinical-stage, vopratelimab, a
monoclonal antibody that binds to and activates ICOS, and JTX-4014,
a PD-1 inhibitor intended for combination use with Jounce’s broader
pipeline. Vopratelimab is currently being assessed in a Phase 2
clinical trial, EMERGE, and Jounce plans to initiate a biomarker
trial using TISvopra for patient selection, SELECT, to assess
vopratelimab in combination with JTX-4014. The next development
candidate to emerge from Jounce’s Translational Science Platform is
JTX-1811, a monoclonal antibody designed to selectively deplete T
regulatory cells in the tumor microenvironment. JTX-1811 is
currently in IND-enabling activities. In addition, Jounce has
exclusively licensed worldwide rights to JTX-8064, a LILRB2
receptor antagonist, to Celgene Corporation, a wholly-owned
subsidiary of Bristol-Myers Squibb Company. For more information,
please visit www.jouncetx.com.
Investor and Media Contact: Komal Joshi Jounce
Therapeutics, Inc. (857) 320-2523 kjoshi@jouncetx.com
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Sep 2023 to Sep 2024